Retinal Vein Occlusion Treatment Market Report 2024

Where is the largest and fastest growing market for retinal vein occlusion treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The retinal vein occlusion treatment market size has grown strongly in recent years. It will grow from $2.11 billion in 2023 to $2.26 billion in 2024 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to several factors, the adoption of combination therapies addressing various aspects of disease pathophysiology, the increasing prevalence of diabetes and hypertension, expanded access to healthcare services and specialized retinal care, clinical trials showing the effectiveness of new treatment options, and advancements in anti-VEGF therapies.

The retinal vein occlusion treatment market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth during the forecast period can be attributed to factors such as cost-effectiveness and favorable reimbursement policies, patient preference for non-invasive treatments, increased global healthcare spending, a growing aging population, and the development of new drugs and therapies. Key trends expected during this period include advancements in gene therapy, the use of nanotechnology for drug delivery, the application of artificial intelligence (AI) in diagnostics, the rise of telemedicine and remote monitoring, and the development of patient-centric technologies.

The growth of the retinal vein occlusion treatment market is anticipated to increase due to the rising prevalence of eye conditions. Eye conditions encompass a range of disorders affecting vision, from minor irritations and infections to serious issues such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy. Factors contributing to the rise in eye conditions include an aging population and the growing rates of diabetes and hypertension. Retinal vein occlusion treatment focuses on restoring blood flow and reducing inflammation to prevent vision loss and manage related complications. For example, the Centers for Disease Control and Prevention reported in January 2024 that over 3.4 million Americans aged 40 and older were blind or visually impaired, with this number expected to double by 2030. This increase in eye conditions is driving growth in the retinal vein occlusion treatment market.

Key players in the retinal vein occlusion treatment market are developing innovative products such as interchangeable biosimilars to expand treatment options and improve patient access. An interchangeable biosimilar is a biologic drug closely similar to an existing reference biologic, used as an alternative for managing inflammation and fluid leakage. For instance, in May 2024, Biocon Biologics Limited, based in India, received approval from the US Food and Drug Administration for Yesafili (aflibercept-jbvf), an interchangeable biosimilar of EYLEA (aflibercept). This drug serves as a vascular endothelial growth factor (VEGF) inhibitor and is used to treat various ophthalmic conditions, including neovascular age-related macular degeneration (wet AMD), macular edema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (myopic CNV).

In April 2022, Samsung Biologics Co. Ltd., a South Korea-based biotechnology company, acquired Samsung Bioepis for $2.3 billion. This acquisition is expected to boost Samsung Bioepis' sales, operating margins, and capabilities in biosimilar and novel drug development. Samsung Bioepis Co. Ltd. is a South Korean biopharmaceutical company that offers treatment for retinal vein occlusion with its biosimilar product BYOOVIZ (ranibizumab-nuna).

Major companies operating in the retinal vein occlusion treatment market are Roche Holding AG, Bayer AG, Novartis International AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Chengdu Kanghong Pharmaceutical Group Co. Ltd., Spark Therapeutics Inc., Genentech Inc., Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Aerpio Pharmaceuticals Inc., REGENXBIO Inc., Stealth BioTherapeutics Corp., Adverum Biotechnologies Inc., Graybug Vision Inc., Oxurion NV, PanOptica Inc., Clearside Biomedical Inc.

North America was the largest region in the retinal vein occlusion treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal vein occlusion treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinal vein occlusion treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Retinal vein occlusion (RVO) treatment encompasses various approaches aimed at managing complications from blocked retinal blood vessels, focusing on reducing edema and preventing further vision loss.

The primary conditions treated for retinal vein occlusion are central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). CRVO involves a blockage of the central retinal vein, which can lead to vision impairment due to disrupted blood flow and potential retinal damage. Diagnosis often includes optical coherence tomography, fundoscopic examination, and fluorescein angiography. Treatments may involve anti-vascular endothelial growth factor (Anti-VEGF) agents, corticosteroids, and other options. These treatments are used by hospitals, clinics, research institutions, academic facilities, and similar entities.

The retinal vein occlusion treatment market research report is one of a series of new reports that provides retinal vein occlusion treatment market statistics, including retinal vein occlusion treatment industry global market size, regional shares, competitors with a retinal vein occlusion treatment market share, detailed retinal vein occlusion treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal vein occlusion treatment industry. This retinal vein occlusion treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinal vein occlusion treatment market consists of revenues earned by entities by providing services such as laser therapy, medication administration, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinal vein occlusion treatment market also includes sales of vitrectomy equipment, and optical coherence tomography (OCT) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.